Author: admin

  • DMC in ALS

    DMC in ALS

    —

    During the course of their disease, around 90% of patients with ALS develop speech or swallowing difficulties – so-called bulbar symptoms. Around a third of all patients already show bulbar symptoms at the onset of ALS. Dextromethorphan/quinidine (DMC) has established itself as an off-label treatment option to alleviate these symptoms in ALS. In a patient…

  • Together since 2011 – 15 years of APST

    Together since 2011 – 15 years of APST

    —

    2026 is a special year for us: APST is celebrating its 15th anniversary. Since our founding, we have stood for reliable support, dedicated research, and digital services for people with ALS, SMA, and other motor neuron diseases. Thank you for your trust, your loyalty, and the many shared experiences over the past years. We look…

  • The ALS app at the international ALS symposium in San Diego

    The ALS app at the international ALS symposium in San Diego

    —

    On December 4, 2025, the ALS app will be presented at the“ALS App Europe Initiative Meeting” at the International Symposium on ALS/MND in San Diego (USA). The meeting brings together European and American ALS centers, researchers and patient initiatives. You can find out more about the program here: https://symposium.mndassociation.org/programme/satellite-meetings/ The “ALS App Europe Initiative” meeting…

  • Which ALS outpatient clinics use the OPM classification?

    Which ALS outpatient clinics use the OPM classification?

    —

    Following our last newsletter on the introduction of the OPM classification in the ALS app, we have received numerous queries: Which ALS outpatient clinics in Germany already use the OPM classification as part of the “NfL study in ALS”? We are pleased to be able to provide you with a transparent overview. ALS outpatient clinics…

  • Submit your e-prescription in the ALS app at your ALS pharmacy and continue to support ALS research

    Submit your e-prescription in the ALS app at your ALS pharmacy and continue to support ALS research

    —

    You can now submit your e-prescription with your health card via the ALS app at your specialist ALS pharmacy! You can also continue to be supplied via your ALS pharmacy with the e-prescription and take part in ALS research. Have four things ready: Electronic health card. You will find the 6-digit CAN number (“Card Access…

  • The new ALS-OPM classification is now in the ALS app.

    The new ALS-OPM classification is now in the ALS app.

    —

    We are pleased to introduce an important new feature in the ALS app today: The new OPM classification is now live! The OPM classification has been available in the current app version 5.10.4 for iOS (Apple) and Android (Google) since yesterday. What does the OPM classification mean? The phenotype of ALS – i.e. the individual…

  • Patient survey on THC:CBD in people with ALS

    Patient survey on THC:CBD in people with ALS

    —

    The THC:CBD patient survey is a systematic survey of 130 patients with amyotrophic lateral sclerosis (ALS), in which important findings on experience and satisfaction with treatment with cannabis-containing medicines containing tetrahydrocannabinol (THC) and cannabidiol (CBD) are obtained. Cannabis-containing treatment for ALS Medicines containing cannabis are used for severe illnesses when conventional medicines are not sufficiently…

  • New medication module in the outpatient partner care portal

    New medication module in the outpatient partner care portal

    —

    We are pleased to inform you that we have completely revised our medication module. With the new version, we want to make the medication supply processes more transparent, efficient and clearer. It went live in the Ambulanzpartner care portal on September 22, 2025. The old and new medication modules will be available in parallel in…

  • Patient survey on eye control glasses for people with ALS

    Patient survey on eye control glasses for people with ALS

    —

    The patient survey on eye control glasses is a nationwide, systematic survey of patients with amyotrophic lateral sclerosis (ALS). The aim of the survey is to gain important insights into expectations of the eye-control glasses as well as experiences and satisfaction following treatment with the innovative aid. Drive the wheelchair safely with eye control glasses…

  • ALS Pharmacy Program Expands Its Network in Germany

    ALS Pharmacy Program Expands Its Network in Germany

    —

    The ALS Pharmacy Program is being further expanded with the addition of two new specialized pharmacies in Hanover and Quickborn. This development offers patients in these regions of Germany the opportunity to benefit from specialized care close to home. As a next step, the network of “ALS Pharmacies” is currently being expanded in southern Germany,…